SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (810)3/21/1998 1:39:00 AM
From: Vector1  Read Replies (1) of 1826
 
Peter,
There is a big difference between DURA and MGI. First Dura has multiple Respiratory drugs. Virtually all of its products are subject to intense competition on the part of major pharmacuedical companies. As a result they felt that they were being outnumbered and loosing sales to inferior products because of lack of sales coverage. Salagen is an orphan drug, and thus will not have competition for 7 years for Sjogrens. In additon the market for head and neck is not large enough for large pharma to even consider.
Thus their alternatives are to go it alone and keep all of that juicy 90% margin to themselves. Outsource a sales force from a CRO such as Quintelles which will charge about 15-20% for a product like this. Or cut a deal with a pharma that will charge at least that much.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News